Krumerman A, Di Biase L, Gerstenfeld E, Dickfeld T, Verma N, Liberman L, Amara R, Kacorri A, Crosson L, Wilk A, and Ferrick KJ
Background: Premature ventricular contraction (PVC) burden is a risk factor for heart failure and cardiovascular death in patients with structural heart disease. Long-term electrocardiographic monitoring can have a significant impact on PVC burden evaluation by further defining PVC distribution patterns., Objective: This study aimed to ascertain the optimal duration of electrocardiographic monitoring to characterize PVC burden and to understand clinical characteristics associated with frequent PVCs and nonsustained ventricular tachycardia in a large US cohort., Methods: Commercial data (iRhythm's Zio patch) from June 2011 to April 2022 were analyzed. Inclusion criteria were age >18 years, PVC burden ≥5%, and wear period ≥13 days. PVC burden cutoffs were determined on the basis of AHA/ACC/HRS guidelines for very frequent PVCs (10,000-20,000 during 24 hours). Patients were assigned to categories by PVC densities: low, <10%; moderate, 10% to <20%; and high, ≥20%. Mean measured error was assessed at baseline and daily until the wear period's end for overall PVC burden and different PVC densities., Results: Analysis of 106,705 patch monitors revealed a study population with mean age of 70.6 ± 14.6 years (33.6% female). PVC burden was higher in male patients and those >65 years of age. PVC burden mean error decreased from 2.9% at 24 hours to 1.3% at 7 days and 0.7% at 10 days. Number of ventricular tachycardia episodes per patient increased with increasing PVC burden (P < .0001)., Conclusion: Extending ambulatory monitoring beyond 24 hours to 7 days or more improves accuracy of assessing PVC burden. Ventricular tachycardia frequency and duration vary by initial PVC density, highlighting the need for prolonged cardiac monitoring., Competing Interests: Disclosures Luigi DiBiase is a consultant for Biosense Webster, Boston Scientific, Stereotaxis, and St Jude Medical and has received speaker honoraria from Medtronic, AtriCure, EPiEP, and Biotronik. Edward Gerstenfeld has served on advisory boards for Biosense Webster, Adagio Medical, and Boston Scientific; has received lecture honoraria from Medtronic, Biosense Webster, Abbott, and Boston Scientific; and has received a research grant from Abbott. Timm Dickfeld has served on advisory boards for Biosense Webster and InHeart and has received consulting honoraria from Impulse Dynamics. Nishant Verma has received speaker’s fees from Medtronic, Boston Scientific, Abbott, and Zoll. Ardit Kacorri, Lori Crosson, and Alan Wilk are employees of iRhythm Technologies. The other authors have no conflicts of interest to disclose., (Copyright © 2024 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)